Conditions:   Advanced Gastric Cancer;   Gastro-esophageal Junction Cancer
Interventions:   Drug: AUY922;   Drug: Docetaxel or Irinotecan
Sponsor:   Novartis Pharmaceuticals
Not yet recruiting - verified March 2010

Condition:   Severe Aortic Valve Stenosis
Intervention:   Device: Medtronic CoreValve System
Sponsor:   Medtronic Bakken Research Center
Not yet recruiting - verified March 2010

Conditions:   Diabetes Mellitus, Type 2;   Cardiovascular Diseases;   Risk Factors
Interventions:   Drug: Canagliflozin on background standard of care for diabetes;   Drug: Placebo on background standard of care for diabetes
Sponsors:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.;   George Institute, Sydney, Australia
Recruiting - verified February 2010

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: BI 10773;   Drug: BI 10773;   Drug: BI 10773
Sponsor:   Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010

Condition:   Lymphocytic Leukemia, Chronic
Interventions:   Drug: RO5072759;   Drug: rituximab;   Drug: chlorambucil
Sponsors:   Hoffmann-La Roche;   Genentech
Recruiting - verified February 2010

Condition:   Asthma
Intervention:   Biological: Mepolizumab (treatment) - Severe asthma
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: exenatide once weekly;   Drug: insulin detemir
Sponsors:   Amylin Pharmaceuticals, Inc.;   Eli Lilly and Company
Recruiting - verified December 2009

Conditions:   Cough;   Sore Throat;   Nasal Congestion;   Headache;   Fever;   Seasonal Influenza
Interventions:   Drug: Peramivir 600mg;   Drug: Peramivir 10 mg
Sponsors:   BioCryst Pharmaceuticals;   Department of Health and Human Services
Recruiting - verified March 2010

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Placebo;   Drug: GW856553;   Drug: GW856553
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Endometrial Cancer
Interventions:   Drug: BN83495;   Drug: Megestrol Acetate (MA)
Sponsor:   Ipsen
Recruiting - verified February 2010

Conditions:   Colorectal Neoplasms;   Neoplasm Metastasis
Interventions:   Drug: aflibercept (AVE0005);   Drug: oxaliplatin;   Drug: 5-FU;   Drug: Folinic Acid
Sponsor:   Sanofi-Aventis
Recruiting - verified March 2010

Condition:   Non-Hodgkin's Lymphoma
Interventions:   Drug: RO5072759;   Drug: RO5072759;   Drug: CHOP(cyclophosphamide,doxorubicin,vincristine,prednisone);   Drug: FC(fludarabine,cyclophosphamide)
Sponsor:   Hoffmann-La Roche
Recruiting - verified February 2010

Conditions:   Acute Coronary Syndrome;   Myocardial Infarction;   Myocardial Ischemia;   Unstable Angina
Intervention:   Drug: Rivaroxaban; Placebo
Sponsors:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.;   Bayer
Recruiting - verified February 2010

Condition:   Anemia
Interventions:   Drug: methoxy polyethylene glycol-epoetin beta [Mircera];   Drug: methoxy polyethylene glycol-epoetin beta [Mircera];   Drug: ESAs (darbepoetin alfa, epoetin alfa or epoetin beta)
Sponsor:   Hoffmann-La Roche
Recruiting - verified February 2010

Condition:   Asthma
Interventions:   Drug: tiotropium 5mcg/day;   Drug: tiotropium 5mcg/day
Sponsors:   Boehringer Ingelheim Pharmaceuticals;   Pfizer
Recruiting - verified March 2010

Condition:   Melanoma
Interventions:   Biological: OncoVEXGM-CSF;   Biological: GM-CSF
Sponsor:   BioVex Limited
Recruiting - verified March 2010

Condition:   Chronic Lymphocytic Leukemia
Interventions:   Drug: ofatumumab (GSK1841157) infusion;   Drug: chlorambucil, tablets
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Diabetes Mellitus
Interventions:   Drug: Exubera;   Other: Randomized diabetes therapy
Sponsor:   Pfizer
Recruiting - verified March 2010

Conditions:   Esophagogastric Junction Adenocarcinoma;   Gastric Cancer;   Esophageal Cancer
Interventions:   Drug: Capecitabine;   Drug: Epirubicin;   Drug: AMG 102;   Drug: Cisplatin
Sponsor:   Amgen
Recruiting - verified March 2010

Condition:   Coronary Heart Disease
Interventions:   Drug: dalcetrapib;   Drug: Placebo;   Drug: Evidence-based medical care for Acute Coronary Syndrome
Sponsor:   Hoffmann-La Roche
Recruiting - verified March 2010

Condition:   Myocardial Infarction
Interventions:   Drug: tenecteplase;   Drug: enoxaparin;   Drug: clopidogrel;   Procedure: catheterisation;   Procedure: primary PCI
Sponsor:   Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010

Condition:   Non-small Cell Lung Cancer
Interventions:   Drug: erlotinib [Tarceva];   Drug: Alimta or Taxotere
Sponsor:   Hoffmann-La Roche
Recruiting - verified February 2010

Condition:   Epilepsy
Interventions:   Drug: lacosamide;   Drug: lacosamide
Sponsor:   UCB, Inc.
Recruiting - verified March 2010

Condition:   Lymphoma, B-Cell
Interventions:   Drug: bevacizumab [Avastin];   Drug: R-CHOP;   Drug: Placebo
Sponsors:   Hoffmann-La Roche;   Genentech
Recruiting - verified February 2010

Condition:   Colorectal Cancer
Interventions:   Drug: bevacizumab [Avastin];   Drug: Xeloda
Sponsor:   Hoffmann-La Roche
Recruiting - verified February 2010

Condition:   Chronic Lymphocytic Leukemia
Intervention:   Drug: ABT-263
Sponsors:   Abbott;   Genentech
Recruiting - verified January 2010

Condition:   Pain, Postoperative
Interventions:   Drug: pregabalin (Lyrica);   Drug: pregabalin (Lyrica);   Drug: matched placebo
Sponsor:   Pfizer
Recruiting - verified February 2010

Condition:   Non-small Cell Lung Cancer
Interventions:   Drug: AMG 706;   Drug: placebo
Sponsors:   Amgen;   Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010

Conditions:   Lymphoma;   Neutropenia;   Psychosocial Effects of Cancer and Its Treatment;   Small Intestine Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: amoxicillin-clavulanate potassium;   Drug: ciprofloxacin;   Procedure: psychosocial assessment and care;   Procedure: quality-of-life assessment
Sponsor:   Clatterbridge Centre for Oncology
Recruiting - verified May 2007

Conditions:   Mitral Regurgitation;   Coronary Artery Disease
Interventions:   Procedure: Mitral annuloplasty;   Procedure: Coronary Artery Bypass Graft Surgery
Sponsors:   Imperial College London;   Department of Health, United Kingdom;   British Heart Foundation;   British Medical Association;   Hammersmith Hospitals NHS Trust;   St Mary's NHS Trust;   King's College Hospital NHS Trust;   Glasgow Royal Infirmary;   Golden Jubilee National Hospital;   University Hospitals, Leicester;   Nottingham University Hospitals NHS Trust;   Medical University of Silesia;   Papworth Hospital;   Central Manchester University Hospitals NHS Foundation Trust;   United Bristol Healthcare NHS Trust;   Blackpool, Flyde and Wyre Hospitals NHS Foundation Trust;   Oxford Radcliffe Hospitals NHS Trust
Recruiting - verified March 2010

Conditions:   Extrahepatic Bile Duct Cancer;   Gallbladder Cancer;   Liver Cancer
Interventions:   Drug: capecitabine;   Other: clinical observation;   Procedure: adjuvant therapy
Sponsor:   Southampton University Hospitals NHS Trust
Recruiting - verified March 2008

Condition:   Endocrine Tumors
Interventions:   Drug: lanreotide (Autogel formulation);   Other: Placebo
Sponsor:   Ipsen
Recruiting - verified March 2010

Condition:   Sarcoma
Interventions:   Biological: dactinomycin;   Drug: busulfan;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: melphalan;   Drug: vincristine sulfate;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   University Hospitals, Leicester;   National Cancer Institute (NCI);   Children's Cancer and Leukaemia Group;   Societe Francaise Oncologie Pediatrique;   European Organization for Research and Treatment of Cancer;   Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany;   Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria;   Swiss Group for Clinical Cancer Research;   EBMT Solid Tumors Working Party;   Children's Oncology Group
Recruiting - verified March 2010